XPHYF - XPHYF STOCK NEWS

XPhyto Therapeutics Corp. has announced the execution of sales contracts for its Covid-ID Lab with digitallife and pharmacies in Bamberg, Germany. These contracts target communities totaling approximately 153,000 residents, offering COVID-19 PCR testing services. With personnel training and equipment installations already completed, the first order of test kits has been delivered. The company aims to expand its sales engagements in Germany and across Europe while focusing on product commercialization. The Covid-ID Lab provides rapid testing with notable efficiency, catering to various sectors including travel and education.

XPhyto Therapeutics Corp. has announced a successful integration of 3a-diagnostics GmbH into its German operations as of January 24, 2022. This acquisition, initially revealed on December 6, 2021, is aimed at accelerating the launch of the COVID-ID lab test system in Europe. The COVID-ID lab offers rapid 20-minute RT-PCR testing for SARS-CoV-2. The company is enhancing operational synergies and has appointed several key personnel to improve product commercialization and sales.

XPhyto Therapeutics Corp. has appointed Mr. Drahoslav Zdarek as the new Head of Sales for Europe, focusing on the distribution and commercialization of its CE Mark-approved Covid-ID Lab rapid RT-PCR test. With over 25 years in pharmaceutical sales, Zdarek’s expertise will aid expansion across European markets. This appointment follows other key hires aimed at strengthening the company's leadership as it prioritizes the growth of Covid-ID Lab and its biosensor innovations. The test offers quick SARS-CoV-2 detection suitable for diverse customers including airports and medical clinics.

XPhyto Therapeutics Corp. has announced the appointments of Roland Spleiss as the Director of Business Development and Dr. Heinrich Jehle as the Head of Diagnostic Research. With over 25 years of experience, Spleiss aims to enhance product sales and streamline supply chains. Dr. Jehle, an expert in medical diagnostics, previously co-founded 3a-diagnostics GmbH, focusing on innovative biosensor development for rapid pathogen detection. These strategic hires are expected to bolster XPhyto's capabilities in the biosensor and diagnostic market, particularly regarding COVID-19 detection.

XPhyto Therapeutics Corp. is advancing its fast-dissolving CBD oral strips aimed at treating childhood epilepsy, with a planned clinical trial set to begin in January 2022. The company has completed vital preparations for the trial, examining CBD's bioavailability compared to existing treatments, which suffer from low efficiency. If successful, XPhyto's proprietary platform could significantly enhance dosing accuracy and treatment efficacy for epilepsy patients. The global thin film drug market is projected to grow to $15.98 billion by 2024, offering XPhyto a lucrative opportunity in the expanding CBD sector.

XPhyto Therapeutics Corp. has completed its acquisition of 3a-diagnostics GmbH, enhancing its position as a leading biosensor producer in the rapid diagnostics sector. This strategic move, which adds valuable intellectual property and scientific expertise, is expected to yield significant synergies in research, development, and manufacturing. The integration will allow XPhyto to offer next-generation oral biosensors for infectious diseases, including COVID-19, with commercial products anticipated as early as 2022. This acquisition marks another step in XPhyto's growth strategy since its public listing in 2019.

XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) announced the issuance of 1,850,000 stock options at an exercise price of $1.25 per share. Of these, 1,750,000 options expire on November 29, 2026, while 100,000 options expire on November 29, 2023. The options were granted to consultants, directors, and officers and will vest immediately. The company's Option Plan allows for the issuance of up to 10% of outstanding shares on a rolling basis. XPhyto focuses on next-generation drug delivery and diagnostics, targeting European market approvals.

XPhyto Therapeutics Corp. has concluded two non-brokered private placements, raising a total of $7 million. The Equity Offering issued 4.5 million common shares for $4.5 million, while the Debenture Offering generated $2.5 million with convertible debentures. The funds will support the acquisition of 3a-diagnostics GmbH and corporate development. The CFO participated in the Equity Offering, which constitutes a related party transaction. All securities are subject to a hold period until March 26, 2022.

XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) announced the appointment of Mr. Joseph Meagher as Chief Financial Officer. Meagher, a Chartered Professional Accountant with extensive experience in IFRS reporting, is also the CFO at Defence Therapeutics Corp. This follows the previous appointment of Dr. Thomas Beckert as managing director of XP Diagnostics GmbH, indicating a strategic strengthening of XPhyto's leadership. The company focuses on drug delivery and diagnostic innovations across North America and Europe, particularly in regulatory approval for medical products.